2 Top Movers Choose Wisely: Heron Therapeutics, Inc. (HRTX), Mimecast Limited (MIME)

The shares of Heron Therapeutics, Inc. have decreased by more than -34.35% this year alone. The shares recently went up by 3.59% or $0.59 and now trades at $17.03. The shares of Mimecast Limited (NASDAQ:MIME), has jumped by 27.53% year to date as of 08/07/2019. The shares currently trade at $42.89 and have been able to report a change of -9.89% over the past one week.

The stock of Heron Therapeutics, Inc. and Mimecast Limited were two of the most active stocks on Wednesday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

Profitability and Returns

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. The ROI of HRTX is -49.10% while that of MIME is -1.00%. These figures suggest that MIME ventures generate a higher ROI than that of HRTX.

Cash Flow

The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, HRTX’s free cash flow per share is a negative -0.07.

Liquidity and Financial Risk

The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for HRTX is 4.40 and that of MIME is 1.30. This implies that it is easier for HRTX to cover its immediate obligations over the next 12 months than MIME. The debt ratio of HRTX is 0.01 compared to 0.78 for MIME. MIME can be able to settle its long-term debts and thus is a lower financial risk than HRTX.


HRTX currently trades at a P/B of 4.03, and a P/S of 14.48 while MIME trades at a forward P/E of 63.92, a P/B of 15.00, and a P/S of 7.89. This means that looking at the earnings, book values and sales basis, HRTX is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

Analyst Price Targets and Opinions

The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of HRTX is currently at a -59.98% to its one-year price target of 42.55. Looking at its rival pricing, MIME is at a -23.33% relative to its price target of 55.94.

When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), HRTX is given a 1.50 while 1.80 placed for MIME. This means that analysts are more bullish on the outlook for MIME stocks.

Insider Activity and Investor Sentiment

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for HRTX is 21.14 while that of MIME is just 1.22. This means that analysts are more bullish on the forecast for MIME stock.


The stock of Heron Therapeutics, Inc. defeats that of Mimecast Limited when the two are compared, with HRTX taking 7 out of the total factors that were been considered. HRTX happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, HRTX is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for HRTX is better on when it is viewed on short interest.